Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3270771 | 0.85 | CCR5 (0.67) | CCR5 | |
| SCHEMBL13600074 | 0.81 | CCR5 (0.55) | CCR5 | |
| SCHEMBL13600079 | 0.80 | CCR5 (0.50) | CCR5 | |
| SCHEMBL13600096 | 0.79 | CCR5 (0.53) | CCR5 | |
| SCHEMBL13600091 | 0.77 | CCR5 (0.51) | CCR5 | |
| SCHEMBL13600041 | 0.77 | CCR5 (0.52) | CCR5 | |
| SCHEMBL3271886 | 0.76 | CCR5 (0.89) | CCR5 | |
| SCHEMBL13600037 | 0.75 | CCR5 (0.76) | CCR5 | |
| SCHEMBL3270895 | 0.75 | CCR5 (0.90) | CCR5 | |
| SCHEMBL14440791 | 0.74 | CCR5 (0.54) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625905-B2 | Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080103125-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103125-A1 | Heterocylic antiviral compounds | CCR5, ACKR3, CXCR3 | CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.